Common use of Repurchase of Notes at the Option of the Holder Clause in Contracts

Repurchase of Notes at the Option of the Holder. Section 11.01. Offer to ▇▇▇▇▇▇▇▇▇▇ ▇▇ Section 11.02. Early Mandatory Settlement Notice 23 Section 11.03. Procedures for Exercise 23 Section 11.04. Withdrawal of Repurchase Notice 23 Section 11.05. Effect of ▇▇▇▇▇▇▇▇▇▇ ▇▇ Section 11.06. No Sinking Fund 24 Section 12.01. Tax Treatment 24 Section 13.01. Conflict with Trust Indenture Act 25 Section 13.02. Effect of Headings and Table of Contents 25 Section 13.03. Successors and Assigns 25 Section 13.04. Separability 25 Section 13.05. Benefits of Supplemental Indenture 25 Section 13.06. Governing Law and Jury Trial Waiver 25 Section 13.07. Ratification of Indenture 25 Exhibit A – Form of Note FIRST SUPPLEMENTAL INDENTURE dated as of July 1, 2019 (this “Supplemental Indenture”) between CHANGE HEALTHCARE INC., a Delaware corporation (the “Company”), and U.S. BANK N.A., a national banking association, as trustee (the “Trustee”), supplementing the Indenture dated as of July 1, 2019, between the Company and the Trustee (the “Base Indenture”).

Repurchase of Notes at the Option of the Holder. Section 11.01. Offer to ▇▇▇▇▇▇▇▇▇▇ ▇▇ Section 11.02. Early Mandatory Settlement Notice 23 Section 11.03. Procedures for Exercise 23 Section 11.04. Withdrawal of Repurchase Notice 23 Section 11.05. Effect of ▇▇▇▇▇▇▇▇▇▇ ▇▇ Section 11.06. No Sinking Fund 24 Section 12.01. Tax Treatment 24 Section 13.01. Conflict with Trust Indenture Act 25 Section 13.02. Effect of Headings and Table of Contents 25 Section 13.03. Successors and Assigns 25 Section 13.04. Separability 25 Section 13.05. Benefits of Supplemental Indenture 25 Section 13.06. Governing Law and Jury Trial Waiver 25 Section 13.07. Ratification of Indenture 25 Exhibit A – Form of Note FIRST SUPPLEMENTAL INDENTURE dated as of July 1[●], 2019 (this “Supplemental Indenture”) between CHANGE HEALTHCARE INC., a Delaware corporation (the “Company”), and U.S. BANK N.A., a national banking association, as trustee (the “Trustee”), supplementing the Indenture dated as of July 1[●], 2019, between the Company and the Trustee (the “Base Indenture”).